Preparing healthcare companies for success
in the value-based economy

New Access Meter Report
NOW AVAILABLE

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

Congratulations Susan!

Susan Raiola – President of Real Endpoints, was chosen as one of PharmaVOICE’s Top 100 most inspiring people in the pharma industry. These inspirational leaders, representing a wide range of industry sectors and functional areas, have an extraordinary and positive impact on their colleagues, their companies, and the life-sciences ecosystem.

RE’s president recognized for innovation in translating theoretical reimbursement coverage to real access for patients

by Real Endpoints

Real Endpoints (RE), an advisory and analytics firm entirely focused on enhancing appropriate access to healthcare innovation, announced today that its president, Susan Raiola, has been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry.  Susan was honored for her innovations in understanding what works among the plethora of patient and provider support programs and Hubs – and then crafting effective strategies specific to the client’s medicine.

August 6, 2019

read full press release >

Gene Therapies Force Payment Innovation

by Gina Shaw

As effective as new gene therapy treatments may be, high setup costs, variable clinical responses, and issues with reimbursement and coding have resulted in significant losses for some manufacturers and providers. “The one-time administration for these therapies introduces a mismatch with benefits” said Jane F. Barlow, Real Endpoints Chief Clinical Officer. “The cost is front-loaded, but benefits accrue over time, creating a challenge as patients move in and out of plans. This is very different than what we see with chronic medications.”

May 17, 2019

Pharmacy Technology Report

read full article >

Recent Insights

view archive >

June 11, 2019

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.

read full insight article >

February 13, 2019

Examining New Payment Ideas for Curative Therapies

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."

read full insight article >